Iovance Biotherapeutics, Inc.
IOVA
Hisse Senetlerindeki Sıralama
#2785
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical... Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.
Hisse Fiyatı
$14.87
Son senkronizasyon: 2026-10-20
Piyasa Değeri
$6.74B
Değişim (1 gün)
4.64%
Değişim (1 yıl)
555.03%
Ülke
US
Ticaret Iovance Biotherapeutics, Inc. (IOVA)
Kategori
Healthcare
Iovance Biotherapeutics, Inc. (IOVA) için tedavüldeki hisse sayısı
June 2026 itibarıyla tedavüldeki hisse sayısı: 450.19M
Iovance Biotherapeutics, Inc. şirketinin son finansal raporlarına ve hisse fiyatına göre, mevcut tedavüldeki hisse sayısı 450.19M'dir. December 2023 sonunda şirketin 235.13M tedavüldeki hissesi vardı. Tedavüldeki hisse sayısı genellikle hisse bölünmeleri ve hisse geri alımları ile etkilenir.
Iovance Biotherapeutics, Inc. (IOVA) için 2008 - 2026 tarihleri arasındaki hisse geçmişi
Her yıl sonunda tedavüldeki hisse sayısı
| Yıl | Tedavüldeki Hisse Sayısı | Değiştir |
|---|---|---|
| 2026 (TTM) | 450.19M | 55.30% |
| 2024 | 289.88M | 23.28% |
| 2023 | 235.13M | 47.64% |
| 2022 | 159.26M | 3.82% |
| 2021 | 153.41M | 10.92% |
| 2020 | 138.30M | 11.23% |
| 2019 | 124.34M | 27.82% |
| 2018 | 97.28M | 49.10% |
| 2017 | 65.24M | 18.05% |
| 2016 | 55.27M | 24.45% |
| 2015 | 44.41M | 77.74% |
| 2014 | 24.99M | 155.93% |
| 2013 | 9.76M | 1,122.62% |
| 2012 | 798.53K | 5.18% |
| 2011 | 759.24K | 16.37% |
| 2010 | 652.46K | -29.48% |
| 2009 | 925.18K | -23.82% |
| 2008 | 1.21M | 0.00% |
Benzer şirketler veya rakipler için tedavüldeki hisse sayısı
| Şirket | Tedavüldeki Hisse Sayısı | Fark | Ülke |
|---|---|---|---|
| 253.90M | -43.60% |
US
|
|
| 396.00M | -12.04% |
US
|
|
| 478.91M | 6.38% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -86.19% |
NL
|
